terbogrel

Also Known As:

(5E)-6-(m-(3-tert-Butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid; 6-(3-(((cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - terbogrel: 2

Experts

1.	Fike, Candice D: 1 article (08/2005)
2.	Kaplowitz, Mark R: 1 article (08/2005)
3.	Zhang, Yongmei: 1 article (08/2005)
4.	Badesch, David B: 1 article (05/2002)
5.	Barst, Robyn J: 1 article (05/2002)
6.	Christman, Brian W: 1 article (05/2002)
7.	Dias, Virgil C: 1 article (05/2002)
8.	Galiè, Nazzareno: 1 article (05/2002)
9.	Higenbottam, Timothy W: 1 article (05/2002)
10.	Hirsch, Andrew M: 1 article (05/2002)

Related Diseases

1.	Pain (Aches) 05/01/2002 - "Although the planned enrollment was 135 patients, the study was halted after only 71 patients had been randomized because of the unforeseen side effect of leg pain, which occurred almost exclusively in patients with terbogrel treatment. " 05/01/2002 - "Inhibition of thromboxane with an orally active agent is feasible in PPH, but the incidence of severe leg pain with terbogrel precludes its use in this disorder. "
2.	Familial Primary Pulmonary Hypertension 05/01/2002 - "Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension."
3.	Pulmonary Hypertension 08/01/2005 - "Terbogrel may ameliorate pulmonary artery dysfunction and attenuate the development of chronic hypoxia-induced pulmonary hypertension in newborns." 08/01/2005 - "Our objective was to determine whether a combined thromboxane synthase inhibitor-receptor antagonist, terbogrel, prevents pulmonary hypertension and the development of aberrant pulmonary arterial responses in newborn piglets exposed to 3 days of hypoxia. "
4.	Hypoxia (Hypoxemia) 08/01/2005 - "Terbogrel may ameliorate pulmonary artery dysfunction and attenuate the development of chronic hypoxia-induced pulmonary hypertension in newborns." 08/01/2005 - "Our objective was to determine whether a combined thromboxane synthase inhibitor-receptor antagonist, terbogrel, prevents pulmonary hypertension and the development of aberrant pulmonary arterial responses in newborn piglets exposed to 3 days of hypoxia. "

Related Drugs and Biologics

1.	Thromboxanes
2.	Thromboxane-A Synthase